News
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of GENE-UP® TYPER, a real-time PCR solution for rapid root cause analysis in the food industry.
Swipe to discover more
-
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid has obtained clearance from the U.S. Food and Drug Administration (FDA). This midplex molecular panel tests for 11 of the most common bacteria, viruses, and parasites associated with gastroenteritis — all from one sample, with results available in approximately one hour. -
Bone and joint infections are complicated by antimicrobial resistance
Osteomyelitis – infection of the bone, and septic arthritis – joint infection, are serious medical conditions that can significantly impact a patient's quality of life. Bone and joint infections, often referred to as (BJIs), are notoriously difficult to treat and successful therapy requires organism-specific antimicrobial therapy at high doses for a prolonged duration.1 Diagnostics can support the identification and management of BJIs, while helping slow the progression of antimicrobial resistance (AMR). -
bioMérieux, Tampa General Hospital and USF Health Host AMR Summit to Drive Action on Antimicrobial Resistance
bioMérieux, Tampa General Hospital (TGH) and USF Health hosted the inaugural U.S. AMR Summit Nov. 12-13 to address the escalating global threat of antimicrobial resistance (AMR).
Enabling Decision-Making
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19